Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Fans flock to Paris to cheer as Lise Davidsen becomes classical music's Taylor SwiftAfter nine years of court oversight, Albuquerque Police now in full compliance with reformsA US museum curator was detained in Turkey on claims of spider smuggling. He says he has permitsIn Mali, thousands replaster the Great Mosque of Djenne, under threat from conflictIllness took away her voice. AI created a replica she carries in her phoneBritish prime minister warns of 'axis of authoritarian states' in preNimmo shakes off injury, comes off bench and hits 2Buffalo Sabres promote minorCity once labeled 'scam capital of America' is now the BEST place to retireA US museum curator was detained in Turkey on claims of spider smuggling. He says he has permits